Horizon Scanning: Pitavastatin versus pravastatin for LDL cholesterol reduction in HIV infected adults with dyslipidaemia

Source: BioSpace Area: News According to a report in BioSpace, results of a comparative superiority study investigating pitavastatin 4mg versus pravastatin 40mg in adult HIV infected patients with dyslipidaemia met its primary endpoint, percent reduction in LDL cholesterol, and reported that, after 12 weeks of therapy, pitavastatin had a significantly greater decrease in LDL cholesterol compared with pravastatin (pitavastatin 31% vs. pravastatin 21% reduction, p<0.001).   The overall incidence of treatment emergent adverse events was 61.1% for pitavastatin and 62.7% for pravastatin.   Pravastatin is often chosen as the statin of choice in patients with HIV as it is implicated in fewer drug interactions. Results were presented at the 20th Conference on Retroviruses and Opportunistic Infections.
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news